Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 194

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 194
---

compensation, increased costs of raw materials, and increased travel expenses related to our U. S. multi-center pivotal trial, offset by
lower third-party contractor expenses.

Marketing expenses

Marketing expenses increased
by $425 from $1,924 for the year ended December 31, 2023 to $2,349 for the year ended December 31, 2024. The increase in marketing expenses
was primarily attributable to increased marketing activities and travel abroad.

General and administrative

General and administrative expenses decreased by
$659 from $7,332 for the year ended December 31, 2023 to $6,673 for the year ended December 31, 2024. The decrease in general and administrative
expenses was primarily due to decreased professional fees (including D& O insurance and legal expenses), offset by increased travel
expenses and increased employee compensation and benefits, including share-based compensation.

Financial expense (income), net

Financial income, net decreased
by $2,241 from $6,539 for the year ended December 31, 2023 to $4,298 for the year ended December 31, 2024. The decrease was primarily
attributable to a decrease in income from remeasurement of warrants and in interest from bank deposits and an increase in interest on
long-term loan, offset by changes in foreign exchange rates.

  Liquidity and Capital Resources  
 ───────────────────────────────────

Sources of Liquidity

We have funded our operations
from inception through December 31, 2024 primarily through gross proceeds of $179,466 from the issuance of our shares and $8,761 from
government grants. The following table provides information regarding our total cash and cash equivalents, short term deposits and restricted
deposits for the periods presented:

                                 As of December 31,                                    
                                 2023                                2024              
 ───────────────────────────────────────────────────────────────────────────────────────
  Cash and cash equivalents      $                       12,657      $         13,724  
  Short-term deposits                                    69,131                45,876  
  Restricted deposits                                     3,152                 3,255  
                                 $                       84,940      $         62,855  

Cash Flows

The following table provides
information regarding our cash flows for the periods presented:

                                                                                     As of December 31,                                      
                                                                                     2023                                 2024               
  Net cash used in operating activities                                              $                       (